SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical ...
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the ...
TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was ...
TriLink BioTechnologies (TriLink ®), a Maravai LifeSciences company (NASDAQ: MRVI) and a recognized leader in the production of high-quality nucleic acid-based products, today renews a multi-year ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
SAN DIEGO - TriLink BioTechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), has launched a new cGMP (current Good Manufacturing Practice) facility dedicated to mRNA drug substance development, ...
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI) and global provider of life science reagents and services, has ...
Wednesday, October 5, 2022 at 11:30am ET | 10:30am CT | 9:30am PT Developing an Analytical Framework for Success using a chemically modified mRNA can be compared with those for traditional biologics,.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback